Cargando…

Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4

Fatty acid binding protein 4 (FABP4) is a fatty acid chaperone, which is induced during adipocyte differentiation. Previously we have shown that FABP4 in endothelial cells is induced by the NOTCH1 signalling pathway, the latter of which is involved in mechanisms of resistance to antiangiogenic tumou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harjes, U, Bridges, E, Gharpure, K M, Roxanis, I, Sheldon, H, Miranda, F, Mangala, L S, Pradeep, S, Lopez-Berestein, G, Ahmed, A, Fielding, B, Sood, A K, Harris, A L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318662/ https://www.ncbi.nlm.nih.gov/pubmed/27568980 http://dx.doi.org/10.1038/onc.2016.256

Ejemplares similares

Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours
por: Dunn, J R, et al.
Publicado: (2006)

FABP4 as a key determinant of metastatic potential of ovarian cancer
por: Gharpure, Kshipra M., et al.
Publicado: (2018)

Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth
por: Oon, Chern Ein, et al.
Publicado: (2017)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Identification of FABP7 as a Potential Biomarker for Predicting Prognosis and Antiangiogenic Drug Efficacy of Glioma
por: Hou, Liubing, et al.
Publicado: (2022)

Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours
por: Nitzsche, B, et al.
Publicado: (2010)

The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
por: Gaballah, K, et al.
Publicado: (2009)

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
por: Verheul, H M W, et al.
Publicado: (1999)

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach
por: Zeisberger, S M, et al.
Publicado: (2006)

Proceedings: Tumour inhibitory triazenes.
por: Wilman, D. E.
Publicado: (1975)

The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer
por: da Motta, L L, et al.
Publicado: (2017)

The Inhibitory Effect of Acenaphthenequinone-Bisulphite upon Tumour Growth in Mice
por: Pearson, A. E. G., et al.
Publicado: (1955)

The significance of tumour microarchitectural features in breast cancer prognosis: a digital image analysis
por: Roxanis, I., et al.
Publicado: (2018)

Proceedings: Mechanism of action of tumour inhibitory nitrosoureas.
por: Connors, T. A., et al.
Publicado: (1975)

The Inhibitory Effect of 9: 10-Phenanthraquinone upon Tumour Growth in Mice
por: Powell, A. K.
Publicado: (1951)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours
por: Cianfrocca, M E, et al.
Publicado: (2006)

Oxidative stress specifically downregulates survivin to promote breast tumour formation
por: Pervin, S, et al.
Publicado: (2013)

Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation
por: Marsh, H P, et al.
Publicado: (2003)

Epigenetic-Mediated Downregulation of μ-Protocadherin in Colorectal Tumours
por: Mateusz, Bujko, et al.
Publicado: (2015)

Changes in the Mitotic Index of the Landschütz Ascites Tumour after Treatment with Tumour-Inhibitory or Non-Inhibitory Samples of Gum Tragacanth or with Gum Karaya
por: Mayhew, E., et al.
Publicado: (1964)

Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines.
por: Lewis, A. D., et al.
Publicado: (1989)

Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma
por: Sasamura, H, et al.
Publicado: (2002)

FABP1 and FABP2 as markers of diabetic nephropathy
por: Tsai, I-Ting, et al.
Publicado: (2020)

Hypoxia Mediated Downregulation of miRNA Biogenesis Promotes Tumor Progression
por: Rupaimoole, Rajesha, et al.
Publicado: (2014)

Tumour‐derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour‐bearing mice
por: Kandarian, Susan C., et al.
Publicado: (2018)

The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy
por: Seed, Robert I., et al.
Publicado: (2019)

Breast tumour angiogenesis
por: Fox, Stephen B, et al.
Publicado: (2007)

Attempted Tumour Therapy Complicated by a Viroid Associate of the Tumour
por: Lapis, K., et al.
Publicado: (1962)

Pan‐cancer landscape of tumour endothelial cells pinpoints insulin receptor as a novel antiangiogenic target and predicts immunotherapy response
por: Zheng, Yongqiang, et al.
Publicado: (2023)

Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts.
por: Woodruff, M. F., et al.
Publicado: (1966)

Tumour Suppressor Neuron Navigator 3 and Matrix Metalloproteinase 14 are Co-expressed in Most Melanomas but Downregulated in Thick Tumours
por: BUGAEVA, Olga, et al.
Publicado: (2023)

REporting recommendations for tumour MARKer prognostic studies (REMARK)
por: Harris, A L
Publicado: (2005)

Endothelial cell metabolism and implications for cancer therapy
por: Harjes, U, et al.
Publicado: (2012)

Transduodenal excision of ampullary tumours.
por: Bohra, A. K., et al.
Publicado: (2002)

Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors
por: Dhawan, Andrew, et al.
Publicado: (2018)

High expression of FABP4 and FABP6 in patients with colorectal cancer
por: Zhang, Yaqin, et al.
Publicado: (2019)

Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models
por: Harris, Emily M., et al.
Publicado: (2018)

Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
por: Rittling, S R, et al.
Publicado: (2014)

Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours
por: Meyer, Tim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hg9gunjo8fo4r4cuqg8hr393tr